 |
|
|
|
|
|
 |
Learn about our UK operations.
|
|
|
|
|
|
|
|
|
|
|
|
 |
Explore opportunities in our entreprenuerial culture.
|
|
|
|
|
|
|
|
|
|
|
|
 |
Learn what's new for Genzyme in the UK.
|
|
|
|
|
|
|
|
|
|
|
|
 |
Find out what is new in our research and development.
|
|
|
|
|
|
|
|
Genzyme
Exceptional Supply for Renagel
This new section on “Our Products” page is to provide access to the
Exceptional Supply form for Renagel and is applicable only for qualified
pharmacists, licensed to dispense Renagel in the UK. More>
|
Genzyme Corporation’s generous benefaction to enable the creation of a key clinical academic post for Multiple Sclerosis, Neuroimmunological Diseases
The University of Cambridge announced today that Genzyme Corporation, a diversified, global biotechnology company with significant operations in Cambridge and across the United Kingdom, has made a generous benefaction to endow a key clinical academic post at the university dedicated to the advancement of fundamental and translational research in the field of multiple sclerosis and other neuroimmunological diseases. More>
|
New ‘Stem Cell Mobilisation’ Technology Accepted For Use by the Scottish Medicines Consortium
Genzyme UK today welcomes the decision by the Scottish Medicines Consortium (SMC) to accept Mozobil® (plerixafor) for use within NHS Scotland. Mozobil is a new ‘stem cell mobilisation’ therapy which is aimed at improving results for patients who are undergoing stem cell transplantation as part of their treatment for the blood cancers multiple myeloma and lymphoma. More>
|
|
|
Genzyme UK Home
Genzyme Corporate Home
